Af­ter pos­i­tive pan­el vote, Sh­iono­gi an­tibi­ot­ic scores US ap­proval

Safe­ty con­cerns linked with Sh­iono­gi’s an­tibi­ot­ic were put to bed by an ex­pert pan­el to the FDA, who large­ly vot­ed to back the drug for com­pli­cat­ed uri­nary tract in­fec­tions (cU­TI) last month. On Fri­day, the US reg­u­la­tor fol­lowed suit, grant­i­ng the treat­ment of­fi­cial ap­proval.

The drug, brand­ed Fetro­ja, will be used in pa­tients whose (cU­TI) is sus­pect­ed to have been caused by Gram-neg­a­tive pathogens, which are in­creas­ing­ly grow­ing re­sis­tant to stan­dard ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.